ArticleBiofilm2026
Pharmacodynamic modeling of colistin and imipenem against
Article in Biofilm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial Pharmacokinetic and Pharmacodynamic Modeling in Airway Mucus.Clinical pharmacokinetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Antibiotic treatment of chronic biofilm-associated infections can be challenging. Characterization of pharmacokinetic/pharmacodynamic (PK/PD) relationships for biofilm-associated infections may be relevant to informing the design of antibiotic treatment regimens for biofilm-associated infections. To this end, we aim to develop a mathematical PK/PD model for planktonic and biofilm bacterial infections and demonstrate how PK/PD simulations can be used to design optimized dosing schedules, using colistin and imipenem as proof-of-concept examples. Methods: Pharmacodynamic models were developed using time-kill assay data from planktonic and alginate-bead biofilm cultures of Results: The developed models incorporated susceptible and resistant bacterial subpopulations and were able to adequately capture the observed time-kill data. Simulation studies identified differences in suppression of bacterial growth dynamics for multiple clinical intravenous and inhalation-based treatment regimens and were used to infer biofilm-specific PK/PD indices associated with ELF target site concentrations. Conclusion: In conclusion, we demonstrate the utility of mathematical modeling for the characterization of PK/PD relationships underlying time-kill kinetic profiles in biofilm-associated infections and their utility in translating experimental findings toward clinically relevant dose-optimization strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.